J Westermann
Overview
Explore the profile of J Westermann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
125
Citations
1198
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aprile E, Aalbers J, Abe K, Ahmed Maouloud S, Althueser L, Andrieu B, et al.
Eur Phys J C Part Fields
. 2024 Aug;
84(8):784.
PMID: 39130092
The multi-staged XENON program at INFN Laboratori Nazionali del Gran Sasso aims to detect dark matter with two-phase liquid xenon time projection chambers of increasing size and sensitivity. The XENONnT...
2.
Aprile E, Abe K, Agostini F, Ahmed Maouloud S, Alfonsi M, Althueser L, et al.
Eur Phys J C Part Fields
. 2022 Jul;
82(7):599.
PMID: 35821975
The selection of low-radioactive construction materials is of the utmost importance for rare-event searches and thus critical to the XENONnT experiment. Results of an extensive radioassay program are reported, in...
3.
Aprile E, Aalbers J, Agostini F, Alfonsi M, Althueser L, Amaro F, et al.
Eur Phys J C Part Fields
. 2021 Nov;
81(4):337.
PMID: 34720714
The selection of low-radioactive construction materials is of utmost importance for the success of low-energy rare event search experiments. Besides radioactive contaminants in the bulk, the emanation of radioactive radon...
4.
Schlenk R, Weber D, Herr W, Wulf G, Salih H, Derigs H, et al.
Leukemia
. 2019 Feb;
33(8):1923-1933.
PMID: 30728457
The aim of this randomized phase-II study was to evaluate the effect of substituting cytarabine by azacitidine in intensive induction therapy of patients with acute myeloid leukemia (AML). Patients were...
5.
Nagel G, Weber D, Fromm E, Erhardt S, Lubbert M, Fiedler W, et al.
Ann Hematol
. 2017 Nov;
96(12):1993-2003.
PMID: 29090343
We describe genetic and clinical characteristics of acute myeloid leukemia (AML) patients according to age from an academic population-based registry. Adult patients with newly diagnosed AML at 63 centers in...
6.
7.
Kayser S, Krzykalla J, Elliott M, Norsworthy K, Gonzales P, Hills R, et al.
Leukemia
. 2017 Mar;
31(11):2347-2354.
PMID: 28322237
Therapy-related acute promyelocytic leukemia (t-APL) is relatively rare, with limited data on outcome after treatment with arsenic trioxide (ATO) compared to standard intensive chemotherapy (CTX). We evaluated 103 adult t-APL...
8.
Nguyen-Hoai T, Pham-Duc M, Gries M, Dorken B, Pezzutto A, Westermann J
Cancer Gene Ther
. 2016 Apr;
23(6):162-7.
PMID: 27056671
Chemokines are key regulators of both innate and adaptive immune responses. CCL4 (macrophage inflammatory protein-1β, MIP-1β) is a CC chemokine that has a broad spectrum of target cells including immature...
9.
Nguyen-Hoai T, Hohn O, Vu M, Baldenhofer G, Sayed Ahmed M, Dorken B, et al.
Cancer Gene Ther
. 2012 Oct;
19(12):880-7.
PMID: 23099886
The aim of this study was to evaluate the efficacy of the chemokine CCL19 (ELC) as an adjuvant for intradermal gene gun delivery of Her2/neu DNA and to investigate the...
10.
Nguyen-Hoai T, Baldenhofer G, Sayed Ahmed M, Pham-Duc M, Vu M, Lipp M, et al.
Cancer Gene Ther
. 2011 Oct;
19(1):69-76.
PMID: 21997231
Secondary lymphoid-tissue chemokine (SLC/CCL21) is a CC chemokine that is constitutively expressed in various lymphoid tissues and binds to chemokine receptor CCR7 on mature dendritic cells (DCs) and distinct T-and...